Smith & Nephew SNATS, Inc. (NYSE:SNN) Stock Has Consensus Target Price of $31.91

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have received a consensus rating of “Reduce” from the eleven ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $31.91.

A number of research analysts have recently weighed in on the stock. Bank of America downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 8th. Wall Street Zen cut shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Saturday. JPMorgan Chase & Co. cut shares of Smith & Nephew SNATS from an “overweight” rating to a “neutral” rating in a report on Thursday, August 6th. Berenberg Bank set a $33.88 price objective on Smith & Nephew SNATS in a research note on Friday, September 11th. Finally, BTIG Research started coverage on Smith & Nephew SNATS in a report on Monday, August 31st. They set a “neutral” rating for the company.

Institutional Trading of Smith & Nephew SNATS

Several hedge funds have recently made changes to their positions in the company. Clearstead Trust LLC purchased a new position in shares of Smith & Nephew SNATS during the 2nd quarter valued at $25,000. Addison Advisors LLC bought a new position in shares of Smith & Nephew SNATS during the 2nd quarter worth $43,000. Allworth Financial LP bought a new position in shares of Smith & Nephew SNATS during the 2nd quarter worth $48,000. Parallel Advisors LLC increased its holdings in Smith & Nephew SNATS by 20.0% in the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock worth $74,000 after acquiring an additional 387 shares during the last quarter. Finally, Root Financial Partners LLC purchased a new stake in Smith & Nephew SNATS in the 3rd quarter worth about $76,000. 25.64% of the stock is currently owned by institutional investors.

Smith & Nephew SNATS Stock Performance

Shares of SNN stock opened at $30.95 on Wednesday. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS has a 52 week low of $26.12 and a 52 week high of $37.09. The firm’s 50-day simple moving average is $28.59 and its two-hundred day simple moving average is $31.03.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company that develops and sells products used in surgery, orthopaedics and wound care. Its offerings include implants for hip and knee replacement, instruments and devices for sports medicine and ear, nose and throat procedures, and products designed to manage wounds and support tissue repair. Founded in 1856 in Hull, England, the company began as a pharmacy business before expanding into medical products. It now serves healthcare providers and patients in markets around the world.